Video

Tarsus execs discuss origins, treating Demodex blepharitis

Author(s):

OT Staff Reports
Conferences|AAO

Tarsus Pharmaceuticals's CEO Bobby Azamian, MD, PhD, and Chairman Michael Ackermann, PhD, speak on the development of their company and the latest updates on their lead candidate product to treat Demodex blepharitis.

See more AAO coverage

Related Videos
Vikas Chopra, MD, at AAO 2024: The role of MIGS in earlier intervention and safer techniques
AAO 2024: Weijie Violet Lin, MD, discusses risk factors for epithelium-off cross-linking
Related Content
AAO 2024: Ocular imaging in the emergency department can provide timely, accurate diagnosis
November 1st 2024

AAO 2024: Ocular imaging in the emergency department can provide timely, accurate diagnosis

Robert Chang, MD, discusses the impact of large language models on glaucoma care and AI in ophthalmology
November 5th 2024

Innovation Series: Putting the buzz of large language models in ophthalmology into perspective with Robert T. Chang, MD

AAO 2024: New drug shows promise as first to protect vision in patients with dry AMD
October 21st 2024

AAO 2024: New drug shows promise as first to protect vision in patients with dry AMD

Comparing micro-bypass implant + phaco vs phaco in POAG
December 23rd 2020

Comparing micro-bypass implant + phaco vs phaco in POAG

AAO 2024: LiGHT trial shows SLT outperforms medications in reducing glaucoma progression over 6 years
October 20th 2024

AAO 2024: LiGHT trial shows SLT outperforms medications in reducing glaucoma progression over 6 years

AAO 2024: New gene therapy shows promise for treatment of retinitis pigmentosa
October 20th 2024

AAO 2024: New gene therapy shows promise for treatment of retinitis pigmentosa

© 2025 MJH Life Sciences

All rights reserved.